Acasti Pharma up after another brokerage starts with bullish rating

Grace Therapeutics

18/07/2019 13:10

** Canada-based drug developer's U.S.-listed shares  ACST.O 
rise 11.7% to $1.53 premarket after Oppenheimer starts with an
"outperform" rating and $7 PT on co's stock 
    ** Oppenheimer's initiation is the second bullish action on
the stock in less than a month, after HC Wainwright started
coverage with a "buy" rating in late-June, sending ACST stock up
~14%  urn:newsml:reuters.com:*:nL4N23X2VG
    ** Besides Oppenheimer, all 3 brokerages covering the stock
rate it "buy" or higher; median PT is $4.38
    ** Oppenheimer says opportunity for co's Krill oil-based
therapy, CaPre, for hypertriglyceridemia is underappreciated 
    ** Says pivotal data from CaPre is just months away, adding
that ACST shares hold upside as the drug approaches
commercialization 
    ** Up to Wednesday's close, stock had risen 14.2% since HC
Wainwright's initiation and was up nearly 65% YTD 

 (Reporting by Manas Mishra in Bengaluru)
 ((Reuters Messaging:
manas.mishra.thomsonreuters.com@reuters.net))